Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome.

Echevarria MI, Awasthi S, Cheng CH, Berglund AE, Rounbehler RJ, Gerke TA, Takhar M, Davicioni E, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Den RB, Cleveland JL, Park JY, Rayford W, Yamoah K.

J Urol. 2019 Aug;202(2):247-255. doi: 10.1097/JU.0000000000000193. Epub 2019 Jul 8.

PMID:
31107158
2.

epiTAD: a web application for visualizing chromosome conformation capture data in the context of genetic epidemiology.

Creed JH, Aden-Buie G, Monteiro AN, Gerke TA.

Bioinformatics. 2019 May 17. pii: btz387. doi: 10.1093/bioinformatics/btz387. [Epub ahead of print]

PMID:
31099399
3.

Aneuploidy drives lethal progression in prostate cancer.

Stopsack KH, Whittaker CA, Gerke TA, Loda M, Kantoff PW, Mucci LA, Amon A.

Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11390-11395. doi: 10.1073/pnas.1902645116. Epub 2019 May 13.

PMID:
31085648
4.

A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2).

Mazzu YZ, Armenia J, Chakraborty G, Yoshikawa Y, Coggins SA, Nandakumar S, Gerke TA, Pomerantz MM, Qiu X, Zhao H, Atiq M, Khan N, Komura K, Lee GM, Fine SW, Bell C, O'Connor E, Long HW, Freedman ML, Kim B, Kantoff PW.

Clin Cancer Res. 2019 Jul 15;25(14):4480-4492. doi: 10.1158/1078-0432.CCR-18-4046. Epub 2019 Apr 17.

PMID:
30996073
5.

Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics.

Ostrom QT, Egan KM, Nabors LB, Gerke T, Thompson RC, Olson JJ, LaRocca R, Chowdhary S, Eckel-Passow JE, Armstrong G, Wiencke JK, Bernstein JL, Claus EB, Il'yasova D, Johansen C, Lachance DH, Lai RK, Merrell RT, Olson SH, Sadetzki S, Schildkraut JM, Shete S, Houlston RS, Jenkins RB, Wrensch MR, Melin B, Amos CI, Huse JT, Barnholtz-Sloan JS, Bondy ML.

Int J Cancer. 2019 Apr 9. doi: 10.1002/ijc.32318. [Epub ahead of print]

PMID:
30963577
6.

Interrelationship Between Health Insurance Status and Prostate Cancer Grade Can Have Critical Impact on Prostate Cancer Disease Control: A Retrospective Cohort Study.

Awasthi S, Gerke T, Williams VL, Asamoah F, Fink AK, Balkrishnan R, Park JY, Yamoah K.

Cancer Control. 2019 Jan-Dec;26(1):1073274819837184. doi: 10.1177/1073274819837184.

7.

Intratumoral Sterol-27-Hydroxylase (CYP27A1) Expression in Relation to Cholesterol Synthesis and Vitamin D Signaling and Its Association with Lethal Prostate Cancer.

Khan NA, Stopsack KH, Allott EH, Gerke T, Giovannucci EL, Mucci LA, Kantoff PW.

Cancer Epidemiol Biomarkers Prev. 2019 Jun;28(6):1052-1058. doi: 10.1158/1055-9965.EPI-18-1083. Epub 2019 Mar 13.

PMID:
30867220
8.

Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment.

Fankhauser CD, Gerke TA, Roth L, Sander S, Grossmann NC, Kranzbühler B, Eberli D, Sulser T, Beyer J, Hermanns T.

J Cancer Res Clin Oncol. 2019 Mar;145(3):781-785. doi: 10.1007/s00432-019-02844-z. Epub 2019 Jan 14.

PMID:
30637464
9.

A Longitudinal Analysis of the Substance Abuse, Violence, and HIV/AIDS (SAVA) Syndemic among Women in the Criminal Justice System.

Jones AA, Gerke T, Striley CW, Osborne V, Whitehead N, Cottler LB.

J Psychoactive Drugs. 2019 Jan-Mar;51(1):58-67. doi: 10.1080/02791072.2018.1562132. Epub 2019 Jan 10.

PMID:
30626264
10.

Low Expression of the Androgen-Induced Tumor Suppressor Gene PLZF and Lethal Prostate Cancer.

Stopsack KH, Gerke T, Tyekucheva S, Mazzu YZ, Lee GM, Chakraborty G, Abida W, Mucci LA, Kantoff PW.

Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):707-714. doi: 10.1158/1055-9965.EPI-18-1014. Epub 2019 Jan 2.

PMID:
30602500
11.

Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer.

Gerke T, Beltran H, Wang X, Lee GM, Sboner A, Karnes RJ, Klein EA, Davicioni E, Yousefi K, Ross AE, Börnigen D, Huttenhower C, Mucci LA, Trock BJ, Sweeney CJ.

Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):584-590. doi: 10.1158/1055-9965.EPI-18-0667. Epub 2018 Nov 12.

PMID:
30420441
12.

Identification of jointly correlated gene sets.

Ren Y, Ay A, Gerke TA, Kahveci T.

J Bioinform Comput Biol. 2018 Oct;16(5):1840019. doi: 10.1142/S021972001840019X.

PMID:
30419787
13.

Optimizing Time to Treatment to Achieve Durable Biochemical Disease Control after Surgery in Prostate Cancer: A Multi-Institutional Cohort Study.

Awasthi S, Gerke T, Park JY, Asamoah FA, Williams VL, Fink AK, Balkrishnan R, Lee DI, Malkowicz SB, Lal P, Dhillon J, Pow-Sang JM, Rebbeck TR, Yamoah K.

Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):570-577. doi: 10.1158/1055-9965.EPI-18-0812. Epub 2018 Nov 9.

PMID:
30413401
14.

Order in The Court? The Association Between Substance Use, Exposure to Violence, Risky Sexual Behaviors & Observed Court Behaviors Among Women Involved in the Criminal Justice System.

Jones AA, Gerke T, Ennis N, Striley CW, Crecelius R, Sullivan JE, Cottler LB.

J Natl Med Assoc. 2019 Apr;111(2):134-147. doi: 10.1016/j.jnma.2018.10.007. Epub 2018 Nov 6.

PMID:
30409715
15.

Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer.

Berglund AE, Rounbehler RJ, Gerke T, Awasthi S, Cheng CH, Takhar M, Davicioni E, Alshalalfa M, Erho N, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Trock BJ, Den RB, Cleveland JL, Park JY, Dhillon J, Yamoah K.

Prostate Cancer Prostatic Dis. 2019 May;22(2):292-302. doi: 10.1038/s41391-018-0103-4. Epub 2018 Oct 26.

PMID:
30367117
16.

Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.

Preston MA, Gerke T, Carlsson SV, Signorello L, Sjoberg DD, Markt SC, Kibel AS, Trinh QD, Steinwandel M, Blot W, Vickers AJ, Lilja H, Mucci LA, Wilson KM.

Eur Urol. 2019 Mar;75(3):399-407. doi: 10.1016/j.eururo.2018.08.032. Epub 2018 Sep 17.

PMID:
30237027
17.

One Step at a Time: A Latent Transitional Analysis on Changes in Substance Use, Exposure to Violence, and HIV/AIDS Risk Behaviors among Female Offenders.

Jones AA, Gerke T, Striley CW, Whitehead N, Osborne V, Cottler LB.

Am J Crim Justice. 2018 Sep;43(3):471-485. doi: 10.1007/s12103-017-9419-1. Epub 2017 Nov 10.

18.

BMI trajectories and risk of overall and grade-specific prostate cancer: An observational cohort study among men seen for prostatic conditions.

Wang K, Chen X, Gerke TA, Bird VY, Ghayee HK, Prosperi M.

Cancer Med. 2018 Oct;7(10):5272-5280. doi: 10.1002/cam4.1747. Epub 2018 Sep 11.

19.

Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease.

Ahearn TU, Peisch S, Pettersson A, Ebot EM, Zhou CK, Graff RE, Sinnott JA, Fazli L, Judson GL, Bismar TA, Rider JR, Gerke T, Chan JM, Fiorentino M, Flavin R, Sesso HD, Finn S, Giovannucci EL, Gleave M, Loda M, Li Z, Pollak M, Mucci LA; Transdisciplinary Prostate Cancer Partnership (ToPCaP).

Carcinogenesis. 2018 Dec 31;39(12):1431-1437. doi: 10.1093/carcin/bgy112.

PMID:
30165429
20.

Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer.

Rounbehler RJ, Berglund AE, Gerke T, Takhar MM, Awasthi S, Li W, Davicioni E, Erho NG, Ross AE, Schaeffer EM, Klein EA, Karnes RJ, Jenkins RB, Cleveland JL, Park JY, Yamoah K.

Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1376-1383. doi: 10.1158/1055-9965.EPI-18-0369. Epub 2018 Aug 14.

PMID:
30108099
21.

Family History of Breast or Prostate Cancer and Prostate Cancer Risk.

Barber L, Gerke T, Markt SC, Peisch SF, Wilson KM, Ahearn T, Giovannucci E, Parmigiani G, Mucci LA.

Clin Cancer Res. 2018 Dec 1;24(23):5910-5917. doi: 10.1158/1078-0432.CCR-18-0370. Epub 2018 Aug 6.

PMID:
30082473
22.

Regular aspirin use and gene expression profiles in prostate cancer patients.

Stopsack KH, Ebot EM, Downer MK, Gerke TA, Rider JR, Kantoff PW, Mucci LA.

Cancer Causes Control. 2018 Aug;29(8):775-784. doi: 10.1007/s10552-018-1049-5. Epub 2018 Jun 18.

PMID:
29915914
23.

ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.

Komura K, Yoshikawa Y, Shimamura T, Chakraborty G, Gerke TA, Hinohara K, Chadalavada K, Jeong SH, Armenia J, Du SY, Mazzu YZ, Taniguchi K, Ibuki N, Meyer CA, Nanjangud GJ, Inamoto T, Lee GM, Mucci LA, Azuma H, Sweeney CJ, Kantoff PW.

J Clin Invest. 2018 Jul 2;128(7):2979-2995. doi: 10.1172/JCI96769. Epub 2018 Jun 4.

24.

Toenail selenium, genetic variation in selenoenzymes and risk and outcome in glioma.

Peeri NC, Creed JH, Anic GM, Thompson RC, Olson JJ, LaRocca RV, Chowdhary SA, Brockman JD, Gerke TA, Nabors LB, Egan KM.

Cancer Epidemiol. 2018 Aug;55:45-51. doi: 10.1016/j.canep.2018.05.002. Epub 2018 May 25.

PMID:
29777993
25.

African-American men and prostate cancer-specific mortality: a competing risk analysis of a large institutional cohort, 1989-2015.

Williams VL, Awasthi S, Fink AK, Pow-Sang JM, Park JY, Gerke T, Yamoah K.

Cancer Med. 2018 May;7(5):2160-2171. doi: 10.1002/cam4.1451. Epub 2018 Mar 30.

26.

Substance Use, Victimization, HIV/AIDS Risk, And Recidivism Among Females in A Therapeutic Justice Program.

Jones AA, O'Leary CC, Striley CW, Gerke T, Crecelius R, Sullivan J, Cottler LB.

J Subst Use. 2018;23(4):415-421. doi: 10.1080/14659891.2018.1436604. Epub 2018 Feb 13.

27.

Interactions of Family History of Breast Cancer with Radiotherapy in Relation to the Risk of Breast Cancer Recurrence.

Li D, Mai V, Gerke T, Pinney SM, Yaghjyan L.

J Breast Cancer. 2017 Dec;20(4):333-339. doi: 10.4048/jbc.2017.20.4.333. Epub 2017 Dec 19.

28.

Height, Obesity, and the Risk of TMPRSS2:ERG-Defined Prostate Cancer.

Graff RE, Ahearn TU, Pettersson A, Ebot EM, Gerke T, Penney KL, Wilson KM, Markt SC, Pernar CH, Gonzalez-Feliciano AG, Song M, Lis RT, Schmidt DR, Vander Heiden MG, Fiorentino M, Giovannucci EL, Loda M, Mucci LA.

Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):193-200. doi: 10.1158/1055-9965.EPI-17-0547. Epub 2017 Nov 22.

29.

MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer.

Pettersson A, Gerke T, Penney KL, Lis RT, Stack EC, Pértega-Gomes N, Zadra G, Tyekucheva S, Giovannucci EL, Mucci LA, Loda M.

Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):201-207. doi: 10.1158/1055-9965.EPI-17-0637. Epub 2017 Nov 15.

30.

The Impact of Revised Discharge Instructions on Patient Satisfaction.

Waniga HM, Gerke T, Shoemaker A, Bourgoine D, Eamranond P.

J Patient Exp. 2016 Sep;3(3):64-68. doi: 10.1177/2374373516666972. Epub 2016 Nov 7.

31.

Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer.

Ebot EM, Gerke T, Labbé DP, Sinnott JA, Zadra G, Rider JR, Tyekucheva S, Wilson KM, Kelly RS, Shui IM, Loda M, Kantoff PW, Finn S, Vander Heiden MG, Brown M, Giovannucci EL, Mucci LA.

Cancer. 2017 Nov 1;123(21):4130-4138. doi: 10.1002/cncr.30831. Epub 2017 Jul 12.

32.

Association between age-related reductions in testosterone and risk of prostate cancer-An analysis of patients' data with prostatic diseases.

Wang K, Chen X, Bird VY, Gerke TA, Manini TM, Prosperi M.

Int J Cancer. 2017 Nov 1;141(9):1783-1793. doi: 10.1002/ijc.30882. Epub 2017 Jul 24.

33.

Cholesterol uptake and regulation in high-grade and lethal prostate cancers.

Stopsack KH, Gerke TA, Andrén O, Andersson SO, Giovannucci EL, Mucci LA, Rider JR.

Carcinogenesis. 2017 Aug 1;38(8):806-811. doi: 10.1093/carcin/bgx058.

34.

Prostate cancer incidence as an iceberg.

Mucci LA, Pernar CH, Peisch S, Gerke T, Wilson KM.

Eur J Epidemiol. 2017 Jun;32(6):477-479. doi: 10.1007/s10654-017-0265-8. Epub 2017 May 30. No abstract available.

35.

The ABC model of prostate cancer: A conceptual framework for the design and interpretation of prognostic studies.

Pettersson A, Gerke T, Fall K, Pawitan Y, Holmberg L, Giovannucci EL, Kantoff PW, Adami HO, Rider JR, Mucci LA; Transdisciplinary Prostate Cancer Partnership (ToPCaP).

Cancer. 2017 May 1;123(9):1490-1496. doi: 10.1002/cncr.30582. Epub 2017 Feb 2. Review.

36.

Re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. Eur Urol 2017;71:907-12.

Fankhauser CD, Mucci LA, Gerke TA.

Eur Urol. 2017 Jul;72(1):e9-e10. doi: 10.1016/j.eururo.2017.01.016. Epub 2017 Jan 17. No abstract available.

37.

Perineural Invasion and Risk of Lethal Prostate Cancer.

Zareba P, Flavin R, Isikbay M, Rider JR, Gerke TA, Finn S, Pettersson A, Giunchi F, Unger RH, Tinianow AM, Andersson SO, Andrén O, Fall K, Fiorentino M, Mucci LA; Transdisciplinary Prostate Cancer Partnership (ToPCaP).

Cancer Epidemiol Biomarkers Prev. 2017 May;26(5):719-726. doi: 10.1158/1055-9965.EPI-16-0237. Epub 2017 Jan 6.

38.

The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study.

Kelly RS, Sinnott JA, Rider JR, Ebot EM, Gerke T, Bowden M, Pettersson A, Loda M, Sesso HD, Kantoff PW, Martin NE, Giovannucci EL, Tyekucheva S, Heiden MV, Mucci LA.

Cancer Metab. 2016 Dec 7;4:22. doi: 10.1186/s40170-016-0161-9. eCollection 2016.

39.

Prognostic Utility of a New mRNA Expression Signature of Gleason Score.

Sinnott JA, Peisch SF, Tyekucheva S, Gerke T, Lis R, Rider JR, Fiorentino M, Stampfer MJ, Mucci LA, Loda M, Penney KL.

Clin Cancer Res. 2017 Jan 1;23(1):81-87. doi: 10.1158/1078-0432.CCR-16-1245. Epub 2016 Sep 23.

40.

Cholesterol Metabolism and Prostate Cancer Lethality.

Stopsack KH, Gerke TA, Sinnott JA, Penney KL, Tyekucheva S, Sesso HD, Andersson SO, Andrén O, Cerhan JR, Giovannucci EL, Mucci LA, Rider JR.

Cancer Res. 2016 Aug 15;76(16):4785-90. doi: 10.1158/0008-5472.CAN-16-0903. Epub 2016 Jun 20.

41.

Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.

Preston MA, Batista JL, Wilson KM, Carlsson SV, Gerke T, Sjoberg DD, Dahl DM, Sesso HD, Feldman AS, Gann PH, Kibel AS, Vickers AJ, Mucci LA.

J Clin Oncol. 2016 Aug 10;34(23):2705-11. doi: 10.1200/JCO.2016.66.7527. Epub 2016 Jun 13.

42.

Changes in bacterial composition of biofilm in a metropolitan drinking water distribution system.

Revetta RP, Gomez-Alvarez V, Gerke TL, Santo Domingo JW, Ashbolt NJ.

J Appl Microbiol. 2016 Jul;121(1):294-305. doi: 10.1111/jam.13150.

43.

The Effectiveness of Individualized Acupuncture Protocols in the Treatment of Gulf War Illness: A Pragmatic Randomized Clinical Trial.

Conboy L, Gerke T, Hsu KY, St John M, Goldstein M, Schnyer R.

PLoS One. 2016 Mar 31;11(3):e0149161. doi: 10.1371/journal.pone.0149161. eCollection 2016.

44.

A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.

Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA, Lotan TL.

J Natl Cancer Inst. 2015 Nov 27;108(2). pii: djv346. doi: 10.1093/jnci/djv346. Print 2016 Feb.

45.

Postoperative rhabdomyolysis following robotic renal and adrenal surgery: a cautionary tale of compounding risk factors.

Terry RS, Gerke T, Mason JB, Sorensen MD, Joseph JP, Dahm P, Su LM.

J Robot Surg. 2015 Sep;9(3):195-200. doi: 10.1007/s11701-015-0515-2. Epub 2015 Jun 20.

PMID:
26531199
46.

Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer.

Lu D, Sinnott JA, Valdimarsdóttir U, Fang F, Gerke T, Tyekucheva S, Fiorentino M, Lambe M, Sesso HD, Sweeney CJ, Wilson KM, Giovannucci EL, Loda M, Mucci LA, Fall K.

Clin Cancer Res. 2016 Feb 1;22(3):765-772. doi: 10.1158/1078-0432.CCR-15-0101. Epub 2015 Oct 21.

47.

Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC.

Gerke TA, Martin NE, Ding Z, Nuttall EJ, Stack EC, Giovannucci E, Lis RT, Stampfer MJ, Kantoff PW, Parmigiani G, Loda M, Mucci LA.

Prostate. 2015 Dec;75(16):1926-33. doi: 10.1002/pros.23090. Epub 2015 Sep 7.

48.

Manganese deposition in drinking water distribution systems.

Gerke TL, Little BJ, Barry Maynard J.

Sci Total Environ. 2016 Jan 15;541:184-193. doi: 10.1016/j.scitotenv.2015.09.054. Epub 2015 Sep 24.

PMID:
26409148
49.

Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer.

Martin NE, Gerke T, Sinnott JA, Stack EC, Andrén O, Andersson SO, Johansson JE, Fiorentino M, Finn S, Fedele G, Stampfer M, Kantoff PW, Mucci LA, Loda M.

Mol Cancer Res. 2015 Oct;13(10):1431-40. doi: 10.1158/1541-7786.MCR-14-0569. Epub 2015 Jun 29.

50.

Molecular differences in transition zone and peripheral zone prostate tumors.

Sinnott JA, Rider JR, Carlsson J, Gerke T, Tyekucheva S, Penney KL, Sesso HD, Loda M, Fall K, Stampfer MJ, Mucci LA, Pawitan Y, Andersson SO, Andrén O.

Carcinogenesis. 2015 Jun;36(6):632-8. doi: 10.1093/carcin/bgv051. Epub 2015 Apr 13.

Supplemental Content

Support Center